The University of Chicago Header Logo

Connection

Thomas Gajewski to Tumor Microenvironment

Back to Details
This is a "connection" page, showing publications Thomas Gajewski has written about Tumor Microenvironment.
Thomas Gajewski
Connection Strength
7.015
Tumor Microenvironment
  1. Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 05 28; 43(5):114141.
    View in: PubMed
    Score: 0.627
  2. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med. 2017 02; 214(2):381-400.
    View in: PubMed
    Score: 0.379
  3. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Adv Exp Med Biol. 2017; 1036:19-31.
    View in: PubMed
    Score: 0.378
  4. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
    View in: PubMed
    Score: 0.362
  5. Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. Adv Immunol. 2016; 130:75-93.
    View in: PubMed
    Score: 0.354
  6. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol. 2015 Aug; 42(4):663-71.
    View in: PubMed
    Score: 0.339
  7. Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity. Nature. 2015 Jul 09; 523(7559):231-5.
    View in: PubMed
    Score: 0.337
  8. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19; 11(7):1018-30.
    View in: PubMed
    Score: 0.337
  9. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015 Apr; 36(4):250-6.
    View in: PubMed
    Score: 0.333
  10. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013 Oct; 14(10):1014-22.
    View in: PubMed
    Score: 0.302
  11. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013 Aug 28; 5(200):200ra116.
    View in: PubMed
    Score: 0.300
  12. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013 Apr; 25(2):268-76.
    View in: PubMed
    Score: 0.292
  13. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011 Apr; 23(2):286-92.
    View in: PubMed
    Score: 0.249
  14. PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells. Cancer Immunol Res. 2025 Apr 02; 13(4):547-559.
    View in: PubMed
    Score: 0.167
  15. Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy. J Immunother Cancer. 2024 Oct 26; 12(10).
    View in: PubMed
    Score: 0.162
  16. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration. J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.137
  17. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.131
  18. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.129
  19. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clin Cancer Res. 2019 07 15; 25(14):4202-4210.
    View in: PubMed
    Score: 0.110
  20. WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019 May 15; 25(10):3074-3083.
    View in: PubMed
    Score: 0.109
  21. Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res. 2018 01; 6(1):14-24.
    View in: PubMed
    Score: 0.100
  22. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 02; 171(4):934-949.e16.
    View in: PubMed
    Score: 0.100
  23. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017 05 08; 31(5):711-723.e4.
    View in: PubMed
    Score: 0.097
  24. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A. 2016 11 29; 113(48):E7759-E7768.
    View in: PubMed
    Score: 0.094
  25. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest. 2016 09 01; 126(9):3389-402.
    View in: PubMed
    Score: 0.092
  26. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016 07 01; 126(7):2404-11.
    View in: PubMed
    Score: 0.091
  27. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27; 350(6264):1084-9.
    View in: PubMed
    Score: 0.087
  28. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clin Cancer Res. 2015 Nov 01; 21(21):4774-9.
    View in: PubMed
    Score: 0.086
  29. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine. 2016 Jan; 77:245-7.
    View in: PubMed
    Score: 0.086
  30. New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015 Apr; 26(2):175-8.
    View in: PubMed
    Score: 0.082
  31. Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature. J Immunol. 2014 Oct 15; 193(8):4254-60.
    View in: PubMed
    Score: 0.080
  32. Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses. Cancer Cell. 2014 Jan 13; 25(1):37-48.
    View in: PubMed
    Score: 0.077
  33. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
    View in: PubMed
    Score: 0.062
  34. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan; 637(8048):1218-1227.
    View in: PubMed
    Score: 0.041
  35. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024 Jun 10; 42(6):1032-1050.e10.
    View in: PubMed
    Score: 0.039
  36. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). J Transl Med. 2022 09 04; 20(1):391.
    View in: PubMed
    Score: 0.035
  37. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy). J Transl Med. 2021 06 30; 19(1):278.
    View in: PubMed
    Score: 0.032
  38. Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer Res. 2020 11 01; 80(21):4707-4719.
    View in: PubMed
    Score: 0.031
  39. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med. 2020 09 07; 18(1):346.
    View in: PubMed
    Score: 0.030
  40. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10.
    View in: PubMed
    Score: 0.025
  41. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313.
    View in: PubMed
    Score: 0.023
  42. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med. 2015 Nov 30; 13:374.
    View in: PubMed
    Score: 0.022
  43. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014 Nov 20; 41(5):830-42.
    View in: PubMed
    Score: 0.020
  44. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012 Oct 03; 10:205.
    View in: PubMed
    Score: 0.018
  45. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012 Jan 03; 10:1.
    View in: PubMed
    Score: 0.017
  46. Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. J Transl Med. 2011 May 12; 9:60.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.